Careful consideration of the benefit to the mother and the risk to the fetus is required when prescribing antifungal therapy in pregnancy. Imidazoles are considered safe as topical therapy for fungal skin infections during pregnancy. Nystatin is minimally absorbed and is effective for vaginal therapy. Although vaginal use of the imidazoles is probably safe during the later stages of pregnancy, their systemic absorption is higher than when applied to the skin. The systemic antifungal drug with which there has been the most experience in pregnancy is amphotericin B. There have been no reports of teratogenesis attributed to this agent. There is evidence to suggest that fluconazole exhibits dose-dependent teratogenic effects; however, it appears to be safe at lower doses (150 mg/day). Ketoconazole, flucytosine, and griseofulvin have been shown to be teratogenic and/or embryotoxic in animals. Iodides have been associated with congenital goiter and should not be used during pregnancy.
Prescribing medications to pregnant women requires a deli-
A number of publications are available to aid clinicians in choosing the safest drug therapy for a pregnant patient [3 - cate balance between the mother's need for treatment and the potential risk of damage to the fetus, including congenital mal -5] . In 1980, the U.S. Food and Drug Administration (FDA) published definitions for pregnancy risk categories [6] . As formations, adverse effects, and the health of the pregnancy itself. Although the dictum ''No drug should be considered shown in table 1, categories A through D and X are assigned in accordance with a product's estimated potential harm to a absolutely safe during pregnancy'' cannot be questioned, most practitioners find this impractical. There are instances in which fetus. These designations provide a grading scale by which to rate a product's relative risk of use in pregnancy. They are pregnant women require medications. Fortunately, scientific data and reports on clinical experience are available to provide derived from pooled data from various pharmacological investigations, animal studies, and clinical experience. Although not guidance when drug therapy during pregnancy is necessary. The use of antifungal medications in pregnancy is addressed absolute, these categories serve as general guidelines and are listed in most major texts and in individual-product monoin this report. References were selected by a MEDLINE search of the English-language literature from 1966 to the present, graphs. It should be noted that manufacturers are not required to provide pregnancy risk categories for drugs marketed before including reference citations and relevant articles.
Pregnant women are susceptible to the same fungal infecDecember 1983. tions as are nonpregnant women, and in some cases their risks are increased. Candidal vaginitis, for example, is common in Topical Therapy nonpregnant patients, but it is more common, more frequently refractory to therapy, and more likely to relapse in pregnant Fungal infections of the skin, hair, and nails are a common clinical problem. The majority of these infections are caused patients [1] . Pregnancy is also associated with more systemic and serious fungal infections. Coccidioidomycosis is believed by dermatophytes, although yeasts such as Malassezia furfur and Candida albicans are also frequently implicated [7] . These to disseminate more frequently in pregnant females [2] . Other systemic mycoses occasionally occur in pregnancy and present infections are usually responsive to topical medications when a small area of the skin is involved. Extensive cutaneous disease therapeutic dilemmas in which two lives are involved. and/or hair or nail involvement, however, often requires a course of oral agents such as ketoconazole, fluconazole, itraconazole, griseofulvin, or terbinafine for resolution. Unfortunately, therapy with both topical and systemic antifungal agents In summary, the only data against use of the imidazoles in pregnancy are those of Rosa et al.
[28] regarding miconazole no increase over the expected number of fetal or neonatal deaths [42] .
during the first trimester. The other imidazoles have been less well studied, and few or no data are available. Although the Imidazoles are the other commonly used topical agents for treatment of yeast vaginitis. In the studies comparing imidaCenters for Disease Control and Prevention previously recommended only nystatin for therapy during the first trimester, zoles to nystatin, imidazoles have uniformly superior cure rates and lower relapse rates [32, 33, 35, 37, 38] . In a study of their most recent recommendations support the use of azolesspecifically, butoconazole, clotrimazole, miconazole, and tervolunteers, 1.4% of the topical vaginal dose of miconazole was recovered in the urine and feces after 96 hours [25] . Although conazole -for vaginal therapy in all trimesters [49] . animal studies utilizing high doses of this drug have demonstrated both embryotoxicity and prolongation of gestation [20] , Systemic Therapy miconazole has been used frequently and, for the most part, safely in human pregnancies.
Systemic antifungal agents have traditionally been regarded as toxic medications, and their use in pregnancy has been limWeisberg reviewed studies in which a total of 471 patients had used miconazole during pregnancy without adverse materited to life-threatening fungal infections. Thus, very little information is available on the use of these drugs in pregnancy. In nal or fetal effects [43] . McNellis et al. demonstrated the overall safety of this product in 291 pregnant women, 43 of whom contrast to the vaginal antifungals, no large-scale trials have been performed, and any existing data on the use of these were in their first trimester [42] . The study by Rosa et al. found an increased risk of birth defects, with a relative risk of 1.02 agents in human pregnancy are from isolated case reports. (95% CI, 0.9 -1.2); however, this was not statistically significant and this study has been the subject of some debate [28] .
Amphotericin B
Fewer data are available concerning the use of clotrimazole in pregnancy. Vaginal absorption is estimated at 3% -10% of The systemic antifungal drug with which there has been the most experience in human pregnancy is amphotericin B [ The most recent formulation to be marketed is amphotericin been only six reports of measurement of amphotericin B concentrations in cord blood [52, 53, 62, 66, 68, 73] . In the three B liposome (AmBisome; Nextar Pharmaceuticals, San Dimas, CA), which is indicated for (1) empirical therapy in febrile, reports in which simultaneous concentrations of maternal and cord blood were reported, the amphotericin B concentrations neutropenic patients; (2) treatment of infections due to Aspergillus species, Candida species, or Cryptococcus species that in these samples were 2.6 and 2.6 mg/mL, 1.9 and 1.3 mg/mL, and 0.32 and 0.12 mg/mL, respectively [52, 53, 66] . Low levels are refractory to or are in patients intolerant of conventional amphotericin B; and (3) treatment of visceral leishmaniasis. of the drug have also been detected in amniotic fluid [52, 66] . Although there is a wide disparity in these results, they Rabbits receiving 0.5 -2 times the recommended human dose had a higher rate of spontaneous abortions than did a control nonetheless confirm that amphotericin B crosses the placenta to enter the fetal circulation and milieu.
group [77] . There has been one report of the use of amphotericin B In table 4 are listed 26 cases in which amphotericin B was used in pregnancy, including 6 first-trimester exposures, 6 secliposome for treatment of Mediterranean visceral leishmaniasis in a pregnant patient during the second trimester. This patient ond-trimester exposures, and 14 third-trimester exposures. Eleven patients received at least 900 mg during pregnancy; of was treated with a total dose of 18 mg/kg and subsequently had a normal, uncomplicated vaginal delivery [68] . To date these, six received at least 1,500 mg. Azotemia was the most common maternal adverse reaction, although anemia, hypokathere have been no reports of either of the other two products having been used in pregnant women. The manufacturers have lemia, acute nephrotoxicity, fever, chills, headache, nausea, and vomiting were also reported. assigned these amphotericin B formulations to risk category B [75 -77]. Possible fetal toxicity was manifested as the following in one case each: transient acidosis with azotemia, anemia, transient maculopapular rash, and respiratory failure requiring mechanical ventilation. None of these toxicities were related to elevated Azoles amphotericin B serum concentrations. Closer examination of the cases in which the mother received ú900 mg of amphoteri-
The azole class of systemic antifungals includes the imidazoles and the more recently introduced triazoles. These drugs cin B during pregnancy reveals that seven of 11 babies showed no adverse effects. Of the 25 cases listed, a single congenital have offered a less toxic alternative to amphotericin B for the treatment of many of the fungi that produce deep-seated malformation was evident (microcephaly with a pilonidal dimple).
infection. The azoles are active against a wide array of fungal pathogens, including C. albicans and most of the agents of A single case report indicates successful treatment of an intraamniotic infection secondary to C. albicans with transcersystemic mycoses, including Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, and to some degree vical amnioinfusion of amphotericin B in a pregnant patient who subsequently had a normal spontaneous vaginal delivery.
Aspergillis fumigatus. As mentioned previously, several azoles are available in topical form. state that the effects of the intravenous form in pregnancy are unknown [3, 4] . The manufacturer assigns the drug to risk The second lipid formulation to be marketed was amphotericin B cholesteryl sulfate complex (Amphotec; Sequus Pharmacategory C [80] .
/ 9c5b$$no08 10-14-98 10:30:12 cidas UC: CID . The mother of these two infants had continued animals are related to maternal toxicity or to direct fetal toxicity is uncertain. The drug does cross the placenta, although to what to receive fluconazole (400 mg daily) for treatment of disseminated coccidioidomycosis. In a pregnancy subsequent to the one degree is unknown [82] .
Of major concern is ketoconazole's well-described inhibition described above, the mother was documented to be noncompliant with fluconazole therapy on the basis of serum drug-concenof both gonadal and adrenal steroid synthesis in humans [83] , resulting in decreased plasma testosterone and adrenal retration measurements, and she delivered a healthy boy. During her fourth pregnancy, the patient was compliant with fluconasponses to adrenocorticotrophic hormone. Theoretically, this endocrine effect might alter the differentiation of sexual organs zole therapy, again documented by serum drug-concentration measurement, and continued to receive fluconazole through the in the human fetus, which is known to be influenced by local concentrations of sex hormones.
fourth month of gestation. She subsequently delivered a girl with congenital abnormalities similar to those of the aboveAn instance of late-trimester exposure in a patient with Cushing's syndrome is the only case in which the use of ketoconamentioned infant [88] .
The fourth case involves a mother, also treated for coccidizole in human pregnancy has been documented. Although the infant (delivered by elective cesarean section) suffered no adoidal meningitis, who received 400 mg/d for the first 5 weeks of gestation, after which time the dosage was changed to verse effects, the authors of this case report emphasize that they knew the sex of the female child prior to institution of 800 mg/d. Fluconazole was withdrawn upon discovery of the pregnancy, and the patient began receiving amphotericin B the drug treatment late in pregnancy [84] . Although the manufacturer has assigned the drug to risk category C, most authoriat 9 weeks' gestation. Therapy with amphotericin B was discontinued and that with fluconazole was restarted at 22 ties advise that this drug not be used in pregnancy [85, 86] .
The triazoles are a newer class of antifungal agents that have weeks, at a dosage of 1,200 mg/d. Spontaneous rupture of the membranes occurred at 31 weeks, and a boy was delivered proven useful in the treatment of systemic fungal infections. The first triazole to become available was fluconazole, available by cesarean section with congenital anomalies similar to those noted above. in both oral and intravenous formulations. Fluconazole has been shown to be teratogenic and embryotoxic at high doses These observations, as well as animal studies conducted by Tiboni, suggest that the teratogenic effects of fluconazole may in rats and is assigned to risk category C by its manufacturer [87] . Congenital anomalies have been reported in four infants be dose-dependent [91] . Inman et al. conducted a prescriptionevent-monitoring study evaluating the safety of fluconazole in whose mothers used fluconazole during pregnancy [88 -90] .
Lee and colleagues reported a case of congenital malformathe treatment of vaginal candidiasis. There was no unusual pattern of fetal abnormalities among 289 women who received tion resembling the genetic disorder Antley-Bixler syndrome in an infant born to a 22-year-old woman receiving fluconazole single or multiple daily doses of fluconazole (150 mg) at some time before or during pregnancy [92] . (400 mg orally once daily) for treatment of disseminated coccidioidomycosis throughout her pregnancy. She experienced More recently, Mastroiacovo and colleagues performed a prospective assessment of pregnancy outcomes after first-tripremature rupture of the membranes at 27 weeks' gestation and subsequently underwent cesarean section. mester exposure to fluconazole. They compared 226 women exposed to this agent (at dosages £150 mg daily) to 452 She delivered a premature female infant with grossly dysmorphic features including radiographic findings of craniosywomen exposed to nonteratogenic agents. They found no difference in prevalences of miscarriages, congenital anomalies, nostosis, humoral-radial fusion, bowed tibia and femur, and bilateral femoral fractures. Other findings at autopsy included or low birth weight [93] . It should be noted that, since the study of Inman et al. [91] , every year thousands of pregnant hypoplasia of nasal bones, cleft palate, contractures of both upper and lower extremities, an incompletely formed right women have inadvertently received fluconazole at daily doses of £150 mg without untoward effects (Pfizer, Groton, CT; thumb, medial deviation of both feet, shortened toes, cranioschisis of the frontal bones, and craniostenosis of the sagittal data on file). This dosage is much lower than the 400 -800-mg daily doses noted in the above case reports. suture. The infant died shortly after birth [88] .
Pursley and colleagues reported two similar cases; the first Less information is available concerning itraconazole. To our knowledge, there have been no reports of its use in human infant was born to a 25-year-old woman receiving fluconazole (800 mg daily) for treatment of C. immitis meningitis [89] . She pregnancy. Itraconazole has been found to be embryotoxic and teratogenic in laboratory animals. Teratogenic effects observed became pregnant and at 7 weeks' gestation was advised to discontinue therapy. The patient chose to continue therapy included major skeletal defects, encephaloceles, and macro-/ 9c5b$$no08 10-14-98 10:30:12 cidas UC: CID glossia. The manufacturer has assigned itraconazole to risk independent epidemiological investigations [3] . These concerns, and the fact that this drug is not prescribed for lifecategory C and recommends use of effective contraception for 2 months following treatment [89, 94] .
threatening fungal infections, indicate that griseofulvin is best avoided during pregnancy [4, 86] .
Flucytosine Terbinafine
Flucytosine (5-fluorocytosine, or 5-FC) is a fluorine analog of cytosine. Its usefulness as an antifungal agent is limited to
The latest systemic antifungal agent to be marketed is terbinafine, an oral squalene epoxidase inhibitor that is indicated yeast infections (due to Candida, Cryptococcus, and Torulopsis species) and is hindered by the prompt development of resisfor onychomycosis of the toenail and fingernail due to dermatophytes. Animal studies have revealed no evidence of harm to tance [78] . Side effects of this oral medication are common and can be severe, including gastrointestinal symptoms, hepatic the fetus. To our knowledge, there have been no reports of the use of terbinafine in pregnancy. The manufacturer has assigned dysfunction, and bone marrow suppression (particularly with blood concentrations ú125 mg/mL).
this product to risk category B, but the lack of human data makes this designation somewhat arbitrary [100] . Flucytosine is teratogenic in rats at doses less than the human dose on a milligram-per-kilogram basis [95] . Its teratogenic properties may be related to the fact that a portion of the Potassium Iodide drug is metabolized to 5-fluorouracil, an antineoplastic agent suspected of causing congenital defects in humans [3] . The
Oral potassium iodide remains the treatment of choice for cutaneous infection caused by Sporothrix schenckii, although drug crosses the human placenta, as evidenced by a case in which drug levels in amniotic fluid and mixed cord blood were the triazole drug itraconazole may be useful in this condition as well [101] . Iodides are generally considered contraindicated measured in a woman with cryptococcal meningitis at 21 weeks' gestation. The mother received the drug for only 1 in pregnancy because of their association with congenital goiter, which can be a fatal condition for the newborn. Among week prior to elective termination of the pregnancy. A concentration of 168 mg/mL was detected in amniotic fluid 4 hours 49 cases reviewed in 1983, 14 deaths occurred secondary to tracheal compression [102] . Although short courses used in after a 2-g oral dosing, and mixed cord blood showed a concentration of 68 mg/mL after the patient had received 4 g that day preoperative management of hyperthyroidism in pregnancy are reported to be safe [3] , the American Academy of Pediatrics [62] .
In addition to the above case, three other cases in which and other authorities advise against the use of iodide-containing drugs during pregnancy [4, 103] . flucytosine was used in human pregnancy have been reported [58, 96, 97] . All were late exposures, with two in the second A single case in which cutaneous sporotrichosis in pregnancy was treated with potassium iodide has been reported [104] . trimester and one in the third. Maternal bone marrow suppression occurred in one case. No adverse fetal effects were noted.
The patient was treated from conception until 2 months prior to delivery, at which time therapy was stopped because of Although the drug is assigned to risk category C by its manufacturer, other authorities believe it is contraindicated in pregconcern about possible goiter formation in the infant. The patient delivered a healthy infant with no evidence of goiter or nancy [73, 86] . thyroid dysfunction. Other cases of cutaneous sporotrichosis in pregnancy have been treated successfully with the local Griseofulvin application of heat [105, 106] . Griseofulvin is an organically derived antifungal agent useful as an oral preparation in the treatment of ringworm. The drug Conclusion is usually well tolerated, although reported side effects include headache and (rarely) other neurological symptoms, gastroinMost of the antifungal medications in current use have become available in the past 30 years; nevertheless, experience testinal distress, and severe hepatotoxic reactions (the latter in patients with acute intermittent porphyria).
with topical and systemic agents in human pregnancy is limited. When prescribing medications to pregnant women, it is good The drug is embryotoxic and teratogenic in animals exposed to high doses [98] . In studies by Rubin and Dvormik, griseofulpractice to exercise added caution with recently released medications. Often a number of years and thousands of exposures vin was reported to have crossed the human placenta [99] . When given to 12 women prior to cesarean section or induction are required for a particular effect to become evident. Animal studies, although suggestive, cannot be entirely exof labor, drug levels in cord blood ranged from 48% to 100% of simultaneous maternal blood levels. The FDA has also retrapolated to human pregnancy. Such was the case with thalidomide, a powerful human teratogen that did not produce malforported an association between first-trimester drug exposure and conjoined twins in two cases, a finding unsupported by two mation in animals. Some effects may be long-delayed in their / 9c5b$$no08 10-14- Amphotericin B is the drug of choice for systemic fungal 
